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Abstract 
Background: There are approximately 72,000 people living with HIV/AIDS (PLHIV) in Peru. Non‑adherence to antiret‑
roviral therapy (ART) is the most important factor for therapeutic failure and the development of resistance. Peru has 
achieved moderate progress in meeting the 90‑90‑90 targets, but only 60% of PLHIV receiving ART are virally sup‑
pressed. The purpose of this study was to understand ART adherence in the Peruvian context, including developing 
sociodemographic and clinical profiles, evaluating the clinical management strategies, and analyzing the relationships 
between the variables and adherence of PLHIV managed at a regional HIV clinic in Lambayeque Province (Northern 
Peru).
Methods: This was a cross‑sectional study with 180 PLHIV adults, non‑randomly but consecutively selected with self‑
reported ART compliance (78.2% of the eligible population). The PLHIV profile (PLHIV‑Pro) and the Simplified Medica‑
tion Adherence Questionnaire (SMAQ) were used to collect sociodemographic information, clinical variables, and 
data specific to ART adherence. Descriptive analysis of sociodemographic and clinical characteristics was performed. 
Bivariate analysis was performed with the Mann–Whitney test, Chi square test, and Yates correction.
Results: The 180 PLHIV sample included 78.9% men, 49.4% heterosexual, 45% with a detectable HIV‑1 viral load 
less than 40 copies/ml, 58.3% not consistently adherent, and only 26.1% receiving Tenofovir + Lamivudine + Efa‑
virenz. Risk factors significant for non‑adherence included concurrent tuberculosis, discomfort with the ART regime, 
and previous pauses in ART. Multivariate analysis of nested models indicated having children is a protector factor for 
adherence.
Conclusions: Self‑reported adherence appeared to be low and the use of first‑line therapy is not being prescribed 
homogeneously. Factors associated with nonadherence are both medical and behavioral, such as having tubercu‑
losis, pausing ART, or experiencing discomfort with ART. The Peruvian government needs to update national techni‑
cal standards, monitor medication availability, and provide education to health care professionals in alignment with 
evidence‑based guidelines and international recommendations. Instruments to measure adherence need to be 
developed and evaluated for use in Latin America.
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Introduction
At the end of 2017, there were approximately 2 million 
[1.5–2.3 million] people living with HIV (PLHIV) in Latin 
America [1, 2]. In Peru, there are approximately 72,000 
[55,000–94,000] PLHIV; however, an estimated 16,250 
of these people are unaware of their infection [3]. HIV 
accounts for 1.8% of the total disease burden and 1.9% of 
the total annual [2.200] deaths in Peru [4]. Each year, an 
additional 2700 HIV infections are diagnosed, with 97% 
related to sexual transmission and men representing 8 
of 10 cases [3]. Men who have sex with men (MSM) and 
transgender women (TW) in Peru are disproportionately 
impacted by HIV [5], with a prevalence as high as 12.4% 
for MSM and 30% for TW compared to less than 0.23% 
for the general population [6, 7]. In addition, MSM and 
TW account for about 60% of new infections [8]. How-
ever, the majority of the HIV literature for these popu-
lations in Peru is based on international surveillance or 
small observational studies focused on the Lima Metro-
politan region [7–12]. As such, the number of MSM and 
TW impacted by HIV/AIDS is largely unknown.
The HIV prevalence worldwide is 1.2%, with the larg-
est prevalence (9.0%) reported in sub-Saharan Africa [13, 
14]. The HIV prevalence has incrementally increased 
from 0.2% to 0.9% in Latin America [15, 16] while the 
prevalence in Peru remains between 0.4% to 0.5% [17]. 
From 2010 to 2015; however, new HIV infections in Peru 
increased by 24% and AIDS-related deaths increased 
by 14% [18], yet across the region there was only a 3% 
increase [19]. This trend is attributed to already infected 
people being diagnosed with increased screenings, prob-
lems with late diagnosis, increased heterosexual diagno-
sis, and HIV + people living longer with ART [20].
Although HIV can be effectively managed with ART 
as a chronic condition [21] rather than a terminal illness 
[22], the call by the Joint United Nations Programme on 
HIV/AIDS (UNAIDS) to enhance ART access in devel-
oping economies, such as Peru, was necessary to move 
governments into action [23]. The Peruvian Ministry of 
Health, or Ministerio de Salud del Perú (MINSA), directs 
HIV care through a series of national regulations and 
guidelines [24–27]. This direction resulted in HIV testing 
with pretest counseling and signed informed consents 
except for pregnancy, and blood and organ donation [25]. 
HIV testing is only free for people with public health 
insurance [28].
Since 2004, ART has been offered without cost in all 
regions of Peru [29] through 145 facilities [3]. In 2017, 
approximately 47,762 PLHIV received ART in Peru, more 
than double from 2000, resulting in the reduction of 
AIDS related mortality from 7.3 to 3.9 per 100,000 peo-
ple from 2000 to 2013 [3, 30]. Overall, Peru has achieved 
moderate progress in achieving the 90-90-90 targets 
for 2020 [31] as an estimated 60% (43,000) of PLHIV 
know their status, 60% (43,000) are receiving ART, and 
60% (24,000) in treatment are virally suppressed [5, 32]. 
Importantly, target measurement is largely based on esti-
mates as there is not a national monitoring system [33].
Objective
Despite the ART scale-up in Peru, including more 
resources dedicated to HIV management in an economi-
cally constrained health sector, surprisingly few studies 
focused on ART adherence have been published from 
Peru [11, 34–40] with none conducted outside the Lima 
Metropolitan region. Yet, ART adherence is problem-
atic as the facilitators and barriers in Peru are not well 
understood [34]. The lack of reliable data from most 
Latin American countries regarding diagnosis, man-
agement, and outcomes makes it difficult to implement 
targeted interventions [1]. As such, the purpose of this 
study was to understand the current state of ART adher-
ence for PLHIV managed at the regional HIV clinic 
located in Northern Peru, (Chiclayo, Lambayeque). The 
study sought to describe the sociodemographic profile of 
PLHIV, to determine the relationships between sociode-
mographic variables and ART adherence, and to identify 
the clinical management compliance with international 
evidence-based guidelines and recommendations.
This study contributes to the limited South American 
knowledge about ART adherence outside major met-
ropolitan areas and fills a gap in the Peruvian literature 
about ART adherence in areas outside of Lima [41]. As 
there are neither regional nor national registries in Peru 
specific to ART adherence, data for this study was man-
ually collected through chart reviews and participant 
interviews. This study is the first reliable source of data 




This was an observational study with a cross-sectional 
design [42]. Since the proportion of the ART adherent 
population is unknown, a non-probabilistic consecu-
tive sampling strategy [43, 44] was implemented in the 
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fall of 2017. From the 230 adult HIV patients managed 
with ART at the regional HIV clinic in Lambayeque, 180 
(78.3%) agreed to participate in this study. The study was 
approved by the regional health system ethics commit-
tee (Protocol 0223-024-16). All participants signed an 
informed consent prior to entering the study. In addition 
to the consent document, researchers explained the pur-
pose of the study, including the objectives, risks, benefits, 
and other ethical aspects. Participants received no finan-
cial compensation and they were able to voluntarily leave 
the study at any time.
Instruments and measures
The data were collected using two instruments: A self-
developed PLHIV profile (PLHIV-Pro) and the Simpli-
fied Medication Adherence Questionnaire (SMAQ). The 
36-item closed-ended PLHIV-Pro was developed from 
the available evidence specific to sociodemographic and 
clinical variables associated with ART adherence and 
engagement in clinical management. The profile was 
validated through an external expert review (two nurses 
and two physicians specialized in HIV care, one patient, 
and one clinical professor with HIV management experi-
ence) and a pilot test was completed with 10 patients to 
evaluate item comprehension, cultural applicability, and 
social acceptance. The Simplified Medication Adherence 
Questionnaire (SMAQ) has 6-tiems, reported to be reli-
able and valid with a 0.75 α-Cronbach, 82% general inter-
observer agreement, 72% sensitivity, and 91% specificity 
[45]. The instrument was piloted with 10 patients; these 
results were excluded from analysis. The time to com-
plete the instruments was 10 to 15 min. The two instru-
ments were administered by four researchers (nurses 
and midwives) to participants following their scheduled 
health consultation in a private examination room. To 
avoid bias, data available in the medical record, such as 
comorbidities, opportunistic infections, viral load, CD4 
levels, place of diagnosis, and year of diagnosis, were ver-
ified with participant permission.
Data analysis
Data were analyzed using SPSS v22.0 [46] and EPIDAT 
v3.1 [47] statistical software packages. First, Kolmogo-
rov–Smirnov normality tests were performed to recog-
nize non-parametric variables [48]. Then, descriptive 
analysis was used for the qualitative variables, including 
frequency distribution, and central tendency and disper-
sion measures were used for the quantitative variables 
[49]. Next, associations were explore between the par-
ticipant characteristics and their ART adherence with the 
Mann–Whitney test [50]. In addition, bivariate analysis of 
qualitative variables was completed using the Chi square 
test, Yates correction, and linear tendency (for ordinal 
variables), with prevalence ratios to calculate associations 
[51]. Finally, multivariate analysis was conducted using a 
binomial linear model nested type [52] considering those 
variables with p-values up to 0.20. A significant “p” value 
lower than 5% and a confidence interval of 95% of the 
corresponding statistic was acceptable.
STROBE compliance
This study is reported in compliance with the STROBE 
(Strengthening The Reporting of OBservational Studies 
in Epidemiology) statement [53] (von Elm et  al., 2007) 
specific to the minimum reporting requirements as 
stated in the cross-sectional study checklist [54].
Results
The study sample included 180 PLHIV, mostly men (80%; 
140) with a median age of 30 years (inter-quartile range 
of 24 to 38.5 years). Almost half of the participants self-
identified as heterosexuals (49.4%; 89) and single (67.8%; 
122) with no children (63.9%; 115), and (19.4%; 35), living 
with a partner, including about half of them living with 
a same sex partner (11.1%; 20). About half the partici-
pants were diagnosed with HIV in a hospital (52.8%; 95), 
with the sexual route the most prevalent cause (46.7%; 84 
homosexual). Participants primarily lived in urban areas 
(75.6%; 136), completed university studies (39.4%, 71), 
and worked self-employed (40%; 72) with a median fam-
ily monthly income of 1000 soles, or about $330 (inter-
quartile range of 625 to 1500 soles). A summary of the 
relevant socio-demographic and ART adherence charac-
teristics are provided in Table 1. Also, the complete data 
are available in the Additional file 1: Table S1.
The median time living with a diagnosis of HIV was 
2  years (IQR 1–3), with most participants (75%; 135) 
starting ART within 1 year (mean 2 years; IQR 1–5). Only 
21.7% (39) of the participants were ART-naive (mean 
1  year; IQR 1–2). For the ART, the most frequent drug 
combination was Zidovudine + Lamivudine + Efavirenz 
(34.4%; 62). More than half of the participants (55%; 99) 
had an undetectable HIV-1 viral load (≤ 40 copies/ml), 
and 63.3% (114) had CD4 monitoring ≥300 cel/μL (mean 
356; IQR 261–527 cel/μL).
Many participants (108) reported comorbidities, 
depression was the most prevalent (42.2%; 76). Among 
participants diagnosed with a sexually transmitted infec-
tion (30%; 54), syphilis was the most frequent (12.8%; 23). 
Most participants shared their HIV diagnosis with a fam-
ily member (79.4%; 143), primarily because they wanted 
emotional support managing the treatment (64.3%; 92). 
Among those who did not share their HIV diagnosis 
with their family (19.4%; 35) the main reason was fear of 
rejection, personal shame, and lack of confidence (32.4%; 
12), or not wanting to cause more problems (32.4%; 12). 
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Table 1 Summary of socio-demographic characteristics of PLHIV and ART adherence at the HIV clinic (2016–2017)
Variable N (%) Non-adherence/total (%) PR [CI 95%] p value
Age** 30 [24–38.50] 29 [24–39] 0.646
Sex
 Male 144 (80.0) 81/144 (56.3)
 Female 36 (20.0) 24/36 (66.7) 0.84 [0.64–1.11] 0.257
Sexual orientation
 Homosexual 63 (35.0) 35/63 (55.6) 0.853
 Heterosexual 89 (49.4) 53/89 (59.6) 1.07 [0.81–1.42]
 Bisexual 28 (15.6) 17/28 (60.7) 1.09 [0.75–1.58]
Marital status
 Single 122 (67.8) 68/122 (55.7) 0.778
 Living with someone/partner 35 (19.4) 22/35 (62.9) 1.13 [0.84–1.52]
 Married 12 (6.7) 8/12 (66.7) 1.20 [0.78–1.84]
 Divorced/widowed 11 (6.1) 7/11 (63.6) 1.14 [0.71–1.83]
Number of children
 0 115 (63.9) 60/115 (52.2) 0.029*
 1 21 (11.7) 13/21 (61.9) 1.19 [0.81–1.73]
 2 25 (13.9) 19/25 (76) 1.46 [1.10–1.93]
 ≥ 3 19 (10.6) 13/19 (68.4) 1.31 [0.92–1.86]
Monthly family incomes** 1000 [625–1500] 1000 [700–1800] 0.302
ART prescription
 ZDV + 3TC + EFV 62 (34.4) 39/62 (62.9) 0.861
 TDF + 3TC + EFV 47 (26.1) 25/47 (53.2) 0.85 [0.61–1.18]
 ABC + 3TC + EFV 26 (14.4) 14/26 (53.8) 0.86 [0.57–1.28]
 TDF + 3TC + ATV + RTV 15 (8.3) 9/15 (60) 0.95 [0.61–1.50]
 Other 30 (16.7) 18/30 (60) 0.95 [0.67–1.35]
Place of diagnosis
 Hospital 95 (52.8) 60/95 (63.2) 0.035*
 Primary Health Center 59 (32.8) 32/59 (54.2) 0.86 [0.65–1.14]
 Private lab or clinic 16 (8.9) 5/16 (31.3) 0.49 [0.24–1.04]
 Ambulatory care 10 (5.6) 8/10 (80) 1.27 [0.90–1.79]
Viral Load 0.513
  > 40 81 (45.0) 51/81 (63) 0.255
  ≤ 40 99 (55.0) 54/99 (54.5) 1.15 [0.90–1.48]
Nivel de CD4** 356 [261–527] 362 [264–516] 0.879
 ≤ 300 66 (36.7) 37/66 (56.1) 0.638
 > 300 114 (63.3) 68/114 (59.6) 0.94 [0.72–1.22]
Years with no ART since diagnosis** 2 [1–5] 2 [1–5] 0.662
 ≥ 1 45 (25) 26/45 (57.8) 0.930
 < 1 135 (75) 79/135 (58.5) 0.99 [0.74–1.32]
Years living with HIV** 2 [1–3] 2 [1–3] 0.980
 ≥ 1 141 (78.3) 86/141 (61) 0.169
 < 1 39 (21.7) 19/39 (48.7) 1.25 [0.88–1.77]
Years taking ART** 1 [1, 2] 1 [1, 2] 0.988
 ≥ 1 122 (67.8) 73/122 (59.8) 0.553
 < 1 58 (32.2) 32/58 (55.2) 1.08 [0.82–1.43]
Opportunistic infection
 Yes 80 (44.4) 43/80 (53.8) 0.265
 No 100 (55.6) 62/100 (62) 0.87 [0.67–1.12]
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A high percentage of participants reported satisfaction 
with the care they received from their physician (90%; 
162) and higher satisfaction with the nursing care (97.2%; 
175).
In terms of ART adherence, 58.3% (105) of the par-
ticipants were not adherent, with 43.3% (78) sometimes 
forgetting to take their ART. In this regard, about half 
stopped their ART regime at some point (46.1%; 83), in 
most of these cases up to 9 days (62.7%; 52), with the 
main cause being “forgetfulness or neglect when attend-
ing a commitment, meeting, or work” (40.7%; 35). Dur-
ing the last month prior to this study, only 10% (18) of 
participants forgot their ART doses for 1–2  days, and 
another 5.6% (10) stopped taking their ART as they felt 
sick. More than half of the participants had side effects 
with their current ART regime (51.1%; 92), including 
heartburn/stomach pain (13.3%; 24) and skin rash (11.7%; 
21) as the most frequent. Some participants (22.2%; 40) 
also acknowledged at least moderate alcohol consump-
tion (Table 2).
The bivariate analysis indicated participant discomfort 
with the treatment regime (p = 0.012; RP = 1.38; IC 95% 
1.07–1.78); stopping treatment at any time (p < 0.001; 
RP = 2.55; IC 95%:1.91–3.41) and stopping treatment 
for up to 9 days (p = 0.001; RP = 1.57; IC 95%:1.03–2.39) 
were significant risk factors for non-adherence (Table 3). 
Other risk factors for non-adherence included concur-
rent TBC (p = 0.013; RP = 5.19; IC 95%:1.42–18.91), feel-
ing sick during the ART regime (p = 0.012; RP = 2.73; 
IC 95%:1.24–6.00), and stopping ART at some point 
(p < 0.001; RP = 17.17; IC 95%:7.19–41). In addition, 
multivariate analysis of nested models indicated hav-
ing children could be a significant protective factor for 
adherence (p = 0.024; RP = 0.25; IC 95%:0.08–0.84).
Discussion
The participants in this study were mostly young (24.0 
to 38.5  years) men (80%; 144). The socioeconomic data 
from this study is similar to the national data [18] and 
data reported by other countries in the region such as 
Colombia [55], reflecting a globalized reality that HIV 
adversely impacts young men. Participants in this study 
were mostly self-identified as heterosexual (49.4%; 89) 
and homosexual (35%; 63). These figures are similar to 
Zidovudine = ZDV; Lamivudine = 3TC; Efavirenz = EFV; Tenofovir = TDF; Abacavir = ABC; Atazanavir = ATV; Ritonavir = RTV; Lopinavir = LPV; PR = prevalence ratio
* p‑value < 0.05 ** Mean [IQR]
Table 1 (continued)
Variable N (%) Non-adherence/total (%) PR [CI 95%] p value
Pulmonary tuberculosis
 Yes 18 (10.0) 6/18 (33.3) 0.023*
 No 162 (90.0) 99/162 (61.1) 0.55 [0.28–1.06]
Side effects with actual ART prescription
 Yes 92 (51.1) 62/92 (67.4) 0.012*
 No 88 (48.9) 43/88 (48.9) 1.38 [1.07–1.78]
Action taken with side effects
 Ask for medical advice 57 (62.0) 38/57 (66.7) 0.031*
 Wait it to stop 28 (30.4) 22/28 (78.6) 1.18 [0.90–1.54]
 Keep taking my ART 4 (4.3) 2/4 (50) 0.75 [0.28–2.03]
 Did not answer 3 (3.3) 0/3 (0) –
ART abandoned at anytime
 Yes 83 (46.1) 72/83 (86.7) 0.001*
 No 97 (53.9) 33/97 (34) 2.55 [1.91–3.41]
Length of ART abandon
 > 30 days 15 (18.1) 9/15 (60) 0.001*
 10–30 days 16 (19.3) 14/16 (87.5) 1.46 [0.93–2.29]
 1–9 days 52 (62.7) 49/52 (94.2) 1.57 [1.03–2.39]
Reason for abandonment
 Forgetfulness or neglect when attending a 
commitment, meeting or work
35 (40.7) 35/35 (100) 0.033*
 Bureaucracy to get access to ART 17 (19.8) 13/17 (76.5) 0.76 [0.59–1.00]
 Lack of privacy or feeling better 11 (12.8) 9/11 (81.8) 0.82 [0.62–1.08]
 Fear of side effects 8 (9.3) 6/8 (75) 0.75 [0.50–1.12]
 Others 15 (17.4) 11/15 (73.3) 0.73 [0.54–1.00]
Page 6 of 12Leyva‑Moral et al. AIDS Res Ther           (2019) 16:22 
the United Kingdom where, in 2011, heterosexual infec-
tions accounted for 49% of all adult 5423 diagnoses [56]. 
Contrarily, in other countries, such as Spain [57] and the 
United States [58] only about 25% were identified as het-
erosexual, with the highest number of diagnoses (53.6%) 
in MSM. The difference in our study could be explained 
by the pervasive discrimination experienced by Les-
bian, Gay, Transgender, and Bisexual people in Latin 
America [59]. For example, more than 45% of Peruvian 
adult women surveyed would not buy vegetables from a 
shopkeeper known to be living with HIV [2]. This type of 
discrimination might influence participant responses to 
some of the questions.
Adequacy of clinical management
Regarding ART clinical management, the World Health 
Organization [60] states, “ART should be started in 
all adults living with HIV, regardless of WHO clinical 
stage and at any CD4 cell count” (p. xxxi). Early ART 
initiation is associated with decreased new infections 
[61]. However, the technical standard published by the 
Peruvian government [27] specify ART based on dif-
ferent criteria (Table 4). In addition, the World Health 
Organization [60] recommendation, and the Peruvian 
government [27], indicate the combination of Tenofo-
vir + Lamivudine + Efavirenz is the first choice for ART; 
however, only 26% of the participants in this study 
received this combination. Yet, more participants, 
34.4% received the less effective alternative treatment 
[60], Zidovudine + Lamivudine + Efavirenz. During 
the data collection process for this study, clinicians and 
participants indicated the recommended ART medica-
tions were not routinely available in the region. Despite 
published information that the WHO recommended 
ART is widely available in Peru, local HIV experts sug-
gested the provinces routinely lack Lamivudine and/
or Tenofovir. This demonstrates the reality reported in 
literature for Metropolitan Lima may differ from the 
experiences in the provinces.
Also, each PLHIV presenting at the regional clinic is 
initially evaluated by a psychologist. In the presence of 
a suspected mental condition, a PLHIV is required to be 
referred to a psychiatrist for diagnosis and clinical man-
agement. Similar to other studies [62–65] most partici-
pants in this study had a depression diagnosis. This is the 
first study to report depression as a problem for PLHIV 
in Peru. Importantly, the local experts reported the ini-
tial psychological evaluations are completed in a timely 
Table 2 Adherence characteristics of people receiving ART at the HIV Clinic (2016–2017)
Variable Category n %
Adherence ≥ 90% Yes 75 41.7
No 105 58.3
Did you ever forget to take your medication? Yes 78 43.3
No 99 55.0
Did not answer 3 1.7
I always take my medication at the indicated time Yes 130 72.2
No 46 25.6
Did not answer 4 2.2
I stop taking my medication when I feel sick Yes 10 5.6
No 164 91.1
Did not answer 6 3.3
I forget to take my medication on the weekends Yes 8 4.4
No 166 92.2
Did not answer 6 3.3
Number of days I forgot to take my medication in the last week None 156 86.7
1 day 17 9.4
2–3 days 2 1.1
4–5 days 2 1.1
> 5 days 3 1.7
Number of days I forgot to take my medication in the last month None 149 82.8
1–2 days 18 10.0
3–5 days 4 2.2
6–10 days 6 3.3
Did not answer 3 1.7
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manner; however, there are limited appointments avail-
able for referrals and continued management.
ART adherence rates
Although the ART adherence rates reported in the lit-
erature are wide-ranging and dependent on the socio-
cultural context, there needs to be a good assessment 
tool to measure adherence in Latin American coun-
tries. Data reported in a meta-analysis from the United 
States reported the adherence rate to be 55%, with good 
adherence deemed to be 80%. When correcting this data 
with the 90% expectation, as is the case in this study, 
good adherence descends to 62% [66]. Furthermore, 
studies [67] with small samples from the region report 
adherence rates for PLHIV as high as 90%. Yet, older but 
slightly large studies in Peru [36] identified higher adher-
ence rates only among people with higher education 
(OR = 0.45. 95% CI 0.27–0.75) and age (OR = 1.05. 95% 
CI 1.02–1.08). Additional research is necessary to meas-
ure ART adherence across Peru.
Table 3 Multivariate analysis of  sociodemographic characteristics and  ART adherence for  people managed at  the  HIV 
clinic (2016–2017)
Variable Bivariate Multivariate
RP [IC 95%] p-valor RP [IC 95%] p-valor
Number of children
 None 0.029* 0.024*
 1 1.19 [0.81–1.73] 0.25 [0.08–0.84]
 2 1.46 [1.10–1.93] 0.24 [0.07–0.83]
 ≥ 3 1.31 [0.92–1.86] 0.21 [0.06–0.77]
Place of diagnosis
 Hospital 0.045*
 Primary Care Center 0.86 [0.65–1.14]
 Private lab or clinic 0.49 [0.24–1.04]
 Ambulatory care 1.27 [0.90–1.79]
TBC
 Yes 0.023* 0.013*
 No 0.55 [0.28–1.06] 5.19 [1.42–18.91]
Complaints about the current ART regime
 Yes 0.012* 0.012*
 No 1.38 [1.07–1.78] 2.73 [1.24–6.00]
Action taken when experiencing side effects
 Visit the physician 0.041*
 Nothing. just wait it to stop 1.18 [0.90–1.54]
 Take my ART anyway 0.75 [0.28–2.03]
 Did not answer –
ART cessation ever
 Yes p < 0.001* p < 0.001*
 No 2.55 [1.91–3.41] 17.17 [7.19–41]
Length of last ART cessation
 > 30 days 0.001*
 10–30 days 1.46 [0.93–2.29]
 1–9 days 1.57 [1.03–2.39]
Reason for cessation ART 
 Forgetfulness or neglect when attending a commitment. meet‑
ing or work
0.033*
 Permissions. paperwork for getting access to ART 0.76 [0.59–1.00]
 My own decision. lack of privacy or wanting to feel better 0.82 [0.62–1.08]
 Fear of side effects 0.75 [0.50–1.12]
 Other 0.73 [0.54–1.00]
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Detectable viral load and ART adherence
In an unpublished undergraduate thesis studying PLHIV 
in Northern Peru, ART adherence was reported to be 
30%, with an association identified between physical and 
mental quality of life and ART adherence (p = 0.03 and 
0.04) [68]. Although adherence in this study was higher, 
almost half of the patients (45%) had a detectable viral 
load. This result must be considered with caution as 
patients in Peru learn to obey physicians and interface 
with the health system with largely passive behaviours. 
As a result, patients who were not adherent might have 
decided to respond affirmatively. In addition, the detect-
able viral load can be partially explained by people begin-
ning ART within the last 6 months. As 32.2% of patients 
were in their first year of ART, they could still be adapt-
ing to the daily medication intake as well as the newness 
of any side effects. Furthermore, the inadequate incor-
poration of the WHO recommended ART for most par-
ticipants could have limited the clinical effectiveness of 
treatment. The policy opportunity is to develop a regional 
database to monitor program outcomes, such as ART 
regimen, ART adherence, and level of viral resistance.
Patient satisfaction and ART adherence
The results indicate complaints about the ART regimen 
were a significant factor associated with non-adherence. 
In the metanalysis by Clay, Nag, Graham, and Naray-
anan [69], PLHIV taking a single pill were significantly 
more adherent in comparison to those taking more than 
one pill at any frequency (odds ratio [OR]: 2.37 [95% CI 
1.68, 3.35],  p <  0.001), twice-daily MTR (OR: 2.53 [95% 
CI 1.13, 5.66],  p =  0.02) and the once-daily multiple tab-
let regimens (OR: 1.81 [95% CI 1.15, 2.84],  p =  0.01). 
Similarly, Raffi et  al. [70] found significantly higher rates 
of ART adherence (89.6%) among those taking a single 
tenofovir-emtricitabine-efavirenz therapy, compared to 
those taking combinations of ART (86.4% > 1 pill once 
daily; 77.0% > 1 daily intake; P <  0.0001). As such, the policy 
implication is for the MINSA to consider the cost to ben-
efit ratio for shifting ART to a one pill per day regimen.
Tuberculosis comorbidity and ART adherence
No prior evidence has been found reporting Tuberculosis 
(TB) comorbidity as a risk factor of ART non-adherence. 
However, research indicates PLHIV have a 20- to 37-fold 
higher risk of active TB than those without HIV [71]. 
The association found in this study can be explained by 
the summative effect of suffering from two chronic con-
ditions, associated with stigma and discrimination, that 
require clinical management for an entire life. Further-
more, this study found interrupted ART at some point 
is a risk factor for non-adherence (p < 0.001; RP = 17.17; 
IC 95%:7.19–41), more significantly for PLHIV with con-
current TB. The literature indicates ART interruptions 
are common, especially in the presence of other chronic 
conditions, due to the resulting fatigue and personal 
attempts to eliminate side effects with treatment [72].
Study limitations
Despite this being one of the larger studies conducted 
in Latin America, and the largest in Peru, this study has 
several limitations. First, the descriptive design with a 
relatively small sample size, compared to studies outside 
the region, was used to calculate frequencies and aver-
ages, and to perform bivariate exploratory analysis. As 
such, the design might not show important positive asso-
ciations. However, the study sample was comprised on 
almost 80% of the available population in the region, so 
the results are at least a good approximation of the local 
reality. Second, access to HIV data, requires locating and 
Table 4 Technical standard (NTS No. 097 MINSA/DGSP-V.02) in  Peru for  comprehensive care of  the  adult with  Human 
Immunodeficiency Virus (HIV) infection
Any person with HIV infection who has symptoms related to immunosuppression (clinical stages 2, 3 and 4 of the WHO 2007 classification)
Any person with HIV infection who has a CD4 T cell count ≤ 500 cells/μL, regardless of the presence of symptoms
Any person with HIV infection, regardless of the presence of symptoms and CD4 T cell count, who has any of the following conditions
  HIV‑related nephropathy
  Neuro‑cognitive impairment associated with HIV
  Non‑HIV neoplasms that require chemotherapy or radiation therapy
  Coinfection with chronic hepatitis B requiring treatment
  Chronic hepatitis C co‑infection requiring treatment
  HIV‑related autoimmune diseases
  Gestation
Anyone with acute HIV infection who has symptoms
Serodiscordant couples
Other cases, according to the criteria of the treating physician after consultation and approval of the Expert Committee on Comprehensive Care for 
Adults with HIV Infection
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reviewing health records in an environment with deficits 
in storage, limitations in standards, and inconsistencies 
in the organization of clinical data. This Peruvian real-
ity can lead to errors in data collection or even missed 
data. Although double-checks were incorporated into 
this study, the possibility for errors could impact the 
results. Third, despite the widespread use of the instru-
ment to calculate adherence, there are few studies that 
establish the positive predictive value; possibly distort-
ing the calculated rates. However, this study included 
a review of the health record with a comparison to the 
laboratory tested viral load as a verification process. 
Fourth, the adherence measurement was cross-sectional; 
therefore, the data is limited to one moment in time 
versus the adherence changes over time (this was not a 
study objective). Fifth, the laboratory values were col-
lected from medical records and referred to the last value 
recorded within the last 6 months. As such, there could 
be variations in lab value recorded with any pending, or 
misplaced, values. Despite these limitations, the result-
ing data was collected in a systematic and rigorous man-
ner. Finally, despite the consecutive sampling strategy 
there was a low TW participation in this study. Clini-
cians report the TW population encounter severe stigma 
and pervasive discrimination in the provinces that forces 
them to remain “incognito” in the health system. In retro-
spect, a proportional quota sampling strategy might have 
addressed this limitation [73, 74].
Conclusion
PLHIV managed at the regional clinic in Lambayeque 
are mainly young men, self-identified as heterosexual, 
urban residents, with high school education, and lower 
incomes. Being co-infected with TB, having complaints 
about the ART regimen, and interrupting ART at some 
point are risk factors for non-adherence. Given the 
adherence rates reported in this study, the analytical 
values observed, and the variations in the ART manage-
ment from the internationally published evidence-based 
standards for care of PLHIV, there are two important 
policy implications. First, the Peruvian national clinical 
practice guidelines for HIV/AIDS need to be evaluated 
and compared with contemporary evidence-based clini-
cal practices and existing international standards of care. 
Second, the clinical practices at the regional level need to 
be evaluated against the national guidelines to determine 
the level of ART regimen compliance. These two recom-
mendations translate into the revision of the technical 
standards to include current international recommen-
dations regarding the initiation of ART and insuring the 
first-line medications are available to all Peruvians, not 
only those living in Lima.
There needs to be further research to develop strategies 
tailored for the Peruvian reality that achieve improve-
ments in empowerment, self-management, and self-care 
that result in better ART adherence, and indirectly reduce 
the number of new infections. Furthermore, processes 
need to be implemented to increase the early diagno-
ses of HIV in order to improve timely treatment, reduce 
complications, and insure the cost-effective distribution 
of limited resources. This implies establishing an inter-
disciplinary community-based intervention to increase 
access to diagnostic testing for HIV in ambulatory set-
tings versus the hospital, and to educate physicians about 
when and how to refer people for HIV testing.
In closing, the experience from this study needs to be 
translated into the development of a permanent local reg-
istry for the province where the regional clinic is located 
to evaluate therapeutic successes and failures. The regis-
try should use the UNAIDS 90-90-90 targets as the pri-
mary outcome measures and then the five segments of 
the HIV Care Continuum to guide the construction of 
process measures. This can be accomplished by imple-
menting an evidence-based interdisciplinary program, 
such as the Adherence Improving Self-Management. 
Overall, the effectiveness of HIV clinical management 
and pharmacological interventions need to be evaluated 
in order to identify the best practices and to disseminate 
the valuable “lessons learned” that facilitate a more effec-
tive scale-up of programs in the region.
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